Balo Andrew K 的 Form 4 申報
Dexcom Inc（DXCM），2021/9/13 申報
- 申報編號
- 0001093557-21-000223
- 申報時間
- 2021/9/13
- 交易日
- 2021/9/9
- 申報延遲
- 4 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 12 筆非衍生性交易。公開市場賣出合計 $306.0 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Balo Andrew KCIK 0001323190 | 高階主管（*） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/9/9 | Common Stock | J其他處分 | −2,498 | $0.00 | $0 | 14,056 | 直接 | |
| 2021/9/9 | Common Stock | J其他取得 | +2,498 | $0.00 | $0 | 13,150 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −1,248 | $541.36 | −$675,617.28 | 11,902 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −15 | $541.76 | −$8,126.4 | 11,887 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −273 | $541.33F6 | −$147,783.09 | 11,614 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −200 | $542.83F7 | −$108,566 | 11,414 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −50 | $543.66 | −$27,183 | 11,364 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −550 | $547.35F8 | −$301,042.5 | 10,814 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −750 | $548.24F9 | −$411,180 | 10,064 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −1,261 | $549.43F10 | −$692,831.23 | 8,803 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −1,200 | $550.36F11 | −$660,432 | 7,603 | 間接 | |
| 2021/9/9 | Common Stock | S賣出處分 | −50 | $551.45 | −$27,572.5 | 7,553 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F6
This transaction was executed in multiple trades at prices ranging from $541.27 to $541.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
- F7
This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
- F8
This transaction was executed in multiple trades at prices ranging from $546.745 to $547.740. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
- F9
This transaction was executed in multiple trades at prices ranging from $547.80 to $548.65. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
- F10
This transaction was executed in multiple trades at prices ranging from $548.93 to $549.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
- F11
This transaction was executed in multiple trades at prices ranging from $549.99 to $550.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
備註
*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development